257 related articles for article (PubMed ID: 19410620)
1. Comparative safety study of three inactivated BTV-8 vaccines in sheep and cattle under field conditions.
Gethmann J; Hüttner K; Heyne H; Probst C; Ziller M; Beer M; Hoffmann B; Mettenleiter TC; Conraths FJ
Vaccine; 2009 Jun; 27(31):4118-26. PubMed ID: 19410620
[TBL] [Abstract][Full Text] [Related]
2. Vaccines against bluetongue in Europe.
Savini G; MacLachlan NJ; Sanchez-Vizcaino JM; Zientara S
Comp Immunol Microbiol Infect Dis; 2008 Mar; 31(2-3):101-20. PubMed ID: 17765305
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep.
Eschbaumer M; Hoffmann B; König P; Teifke JP; Gethmann JM; Conraths FJ; Probst C; Mettenleiter TC; Beer M
Vaccine; 2009 Jun; 27(31):4169-75. PubMed ID: 19406189
[TBL] [Abstract][Full Text] [Related]
4. Protective duration of immunity of an inactivated bluetongue (BTV) serotype 2 vaccine against a virulent BTV serotype 2 challenge in sheep.
Hamers C; Rehbein S; Hudelet P; Blanchet M; Lapostolle B; Cariou C; Duboeuf M; Goutebroze S
Vaccine; 2009 May; 27(21):2789-93. PubMed ID: 19366576
[TBL] [Abstract][Full Text] [Related]
5. Neutralising antibody responses in cattle and sheep following booster vaccination with two commercial inactivated bluetongue virus serotype 8 vaccines.
Bartram DJ; Heasman L; Batten CA; Oura CA; Plana-Durán J; Yuen HM; Wylie AD
Vet J; 2011 May; 188(2):193-6. PubMed ID: 20466568
[TBL] [Abstract][Full Text] [Related]
6. Assessment of efficacy of a bivalent BTV-2 and BTV-4 inactivated vaccine by vaccination and challenge in cattle.
Savini G; Hamers C; Conte A; Migliaccio P; Bonfini B; Teodori L; Di Ventura M; Hudelet P; Schumacher C; Caporale V
Vet Microbiol; 2009 Jan; 133(1-2):1-8. PubMed ID: 18617335
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of humoral response and protective efficacy of three inactivated vaccines against bluetongue virus serotype 8 one year after vaccination of sheep and cattle.
Wäckerlin R; Eschbaumer M; König P; Hoffmann B; Beer M
Vaccine; 2010 Jun; 28(27):4348-55. PubMed ID: 20438878
[TBL] [Abstract][Full Text] [Related]
8. Possible adverse reactions in sheep after vaccination with inactivated BTV vaccines.
González JM; Figueras L; Ortega ME; Lozano M; de Arcaute MR; Royo R; Cebrián LM; Ferrer LM; Fariñas F; de Jalón JA; De las Heras M
Vet Rec; 2010 Jun; 166(24):757-8. PubMed ID: 20543167
[No Abstract] [Full Text] [Related]
9. Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep.
Oura CA; Wood JL; Sanders AJ; Bin-Tarif A; Henstock M; Edwards L; Floyd T; Simmons H; Batten CA
Vaccine; 2009 Dec; 27(52):7326-30. PubMed ID: 19786141
[TBL] [Abstract][Full Text] [Related]
10. An inactivated vaccine for the control of bluetongue virus serotype 16 infection in sheep in Italy.
Savini G; Ronchi GF; Leone A; Ciarelli A; Migliaccio P; Franchi P; Mercante MT; Pini A
Vet Microbiol; 2007 Sep; 124(1-2):140-6. PubMed ID: 17499459
[TBL] [Abstract][Full Text] [Related]
11. Bluetongue vaccines: the past, present and future.
Bhanuprakash V; Indrani BK; Hosamani M; Balamurugan V; Singh RK
Expert Rev Vaccines; 2009 Feb; 8(2):191-204. PubMed ID: 19196199
[TBL] [Abstract][Full Text] [Related]
12. Risk factors associated with the occurrence of undesired effects in sheep and goats after field vaccination with modified-live vaccine against bluetongue virus serotypes 2, 4 and 16.
Savini G; Cannas A; Casaccia C; Di Gialleonardo L; Leone A; Patta C; Nicolussi P
Vet Microbiol; 2010 Nov; 146(1-2):44-50. PubMed ID: 20537822
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats.
Bréard E; Belbis G; Hamers C; Moulin V; Lilin T; Moreau F; Millemann Y; Montange C; Sailleau C; Durand B; Desprat A; Viarouge C; Hoffmann B; de Smit H; Goutebroze S; Hudelet P; Zientara S
Vaccine; 2011 Mar; 29(13):2495-502. PubMed ID: 21256877
[TBL] [Abstract][Full Text] [Related]
14. [Vaccination against bluetongue serotype 8 in the Netherlands].
Kuijk H; Jansen M; Moulin V; Makoschey B
Tijdschr Diergeneeskd; 2008 Dec; 133(23):1006-9. PubMed ID: 19133439
[No Abstract] [Full Text] [Related]
15. Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers.
van der Sluijs MT; Schroer-Joosten DP; Fid-Fourkour A; Vrijenhoek MP; Debyser I; Gregg DA; Dufe DM; Moulin V; Moormann RJ; de Smit AJ
Vaccine; 2012 Jan; 30(3):647-55. PubMed ID: 22107846
[TBL] [Abstract][Full Text] [Related]
16. A DIVA system based on the detection of antibodies to non-structural protein 3 (NS3) of bluetongue virus.
Barros SC; Cruz B; Luís TM; Ramos F; Fagulha T; Duarte M; Henriques M; Fevereiro M
Vet Microbiol; 2009 Jun; 137(3-4):252-9. PubMed ID: 19233575
[TBL] [Abstract][Full Text] [Related]
17. A one-year follow-up of antibody response in cattle and sheep after vaccination with serotype 8- and serotype 1-inactivated BT vaccines.
Zanella G; Bréard E; Sailleau C; Zientara S; Viarouge C; Durand B
Transbound Emerg Dis; 2014 Oct; 61(5):473-6. PubMed ID: 23331382
[TBL] [Abstract][Full Text] [Related]
18. Emergence of bluetongue virus serotype 6 in Europe--German field data and experimental infection of cattle.
Eschbaumer M; Hoffmann B; Moss A; Savini G; Leone A; König P; Zemke J; Conraths F; Beer M
Vet Microbiol; 2010 Jul; 143(2-4):189-95. PubMed ID: 20045271
[TBL] [Abstract][Full Text] [Related]
19. Expression of the major core structural protein (VP7) of bluetongue virus, by a recombinant capripox virus, provides partial protection of sheep against a virulent heterotypic bluetongue virus challenge.
Wade-Evans AM; Romero CH; Mellor P; Takamatsu H; Anderson J; Thevasagayam J; Fleming MJ; Mertens PP; Black DN
Virology; 1996 Jun; 220(1):227-31. PubMed ID: 8659119
[TBL] [Abstract][Full Text] [Related]
20. Bluetongue virus RNA detection by RT-qPCR in blood samples of sheep vaccinated with a commercially available inactivated BTV-8 vaccine.
Steinrigl A; Revilla-Fernández S; Eichinger M; Koefer J; Winter P
Vaccine; 2010 Aug; 28(34):5573-81. PubMed ID: 20600511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
